Please assess the completion status of the following clinical trial:

Trial Title: Propionyl-L-Carnitine in Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have read the Information for the Patient and signed the Informed Consent Form.~* Age comprised between 18 and 75 included.~* If female, not pregnant or nursing.~* For women of childbearing potential, willingness to avoid a pregnancy during the treatment period and for at least 1 month from the last dose of drug.~* Availability of a pancolonoscopy and histology both confirming the diagnosis of active ulcerative colitis.~* Disease Activity Index comprised between 3 and 10, inclusive, (mild to moderate ulcerative colitis).~* On one of the following treatments for ulcerative colitis prior to baseline visit:~  1. Stable background oral aminosalicylates (mesalazine, balsalazide, olsalazine) or sulfasalazine therapy for greater than or equal to 4 weeks prior to baseline assessments.~ 2. Stable background mercaptopurine or azathioprine for greater than or equal to 12 weeks prior to baseline assessments.~Exclusion Criteria:~* First diagnosis of ulcerative colitis.~* Crohn's disease.~* Current or previous (in the last 10 days preceding the screening) use of systemic corticosteroids.~* Use of antibiotics in the last 10 days preceding the screening.~* Use of NSAID's in the last 10 days preceding the screening.~* Use of probiotics in the last 10 days preceding the screening~* Positive stool culture (when performed, according to Investigator's judgment, to assess possible parasitologic infection(s)).~* Significantly impaired liver, renal, pulmonary or cardiovascular function.~* History of colon resection.~* Diverticulitis.~* Diagnosis of proctitis~* Stable rectally administered therapy in the last 10 days.~* Active or chronic infection(s).~* Simultaneous participation in another clinical trial, or participation in any clinical trial involving investigational drugs within 3 months from enrolment into the present study.~* Any physical or psychological condition in a patient that could let the investigator suspect his/her poor compliance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PLC Colon release tablet 1 g (Type: EXPERIMENTAL): 40 patients each arm
- PLC colon release tablet 2 g (Type: EXPERIMENTAL): 40 patients each arm
- Placebo PLC colon release tablet 2 g (Type: PLACEBO_COMPARATOR): 40 patients each arm

Based on this trial design, predict the completion outcome and termination type (if applicable).